NEW YORK (GenomeWeb) – Veracyte announced yesterday that its Afirma Thyroid FNA analysis test, which uses a set of gene expression signatures to differentiate benign thyroid nodules from cancerous ones, will become an Aetna in-network test beginning July 1.

Afirma employs a 142-gene signature to identify benign thyroid nodules in patients whose fine needle aspiration biopsies are deemed indeterminate following traditional cytopathology review and thus face a potentially unnecessary diagnostic surgery.

The test first received a positive coverage decision by Aetna in mid-2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.